Recent Updates
Recently added Catalysts
ENGN Positive Sentiment

enGene to Initiate a BLA Submission for Detalimogene by Year End and Reports New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBC

Wednesday, November 11, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: enGene Therapeutics announced plans to submit a Biologics License Application (BLA) for detalimogene voraplasmid by the end of the year. The company reported new data from the pivotal Cohort 1 of its Phase 2 LEGEND trial, which involved 125 patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer. The results indicate potential efficacy in this challenging patient population.

Market Sentiment Analysis

POSITIVE FACTORS

  • enGene plans to submit a BLA by year-end.
  • New data from the LEGEND trial shows promising results.
  • 125 patients enrolled in the pivotal trial.
  • Focus on high-risk BCG-unresponsive NMIBC.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+23%
120-day peak, hindsight
Typical move
4.1%
average across 2 past catalysts
Cash runway
~40 mo
Low dilution risk
Lead asset
EG-70
Phase 2 · Superficial Bladder Cancer

Full Press Release Details

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced updated results from the pivotal Cohort 1 of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid (also known as detalimogene). Data from Cohort 1, which enrolled 125 patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or

Frequently Asked Questions

What is the purpose of the BLA submission?

The BLA submission aims to seek approval for detalimogene voraplasmid.

How many patients were enrolled in the LEGEND trial?

125 patients were enrolled in Cohort 1 of the LEGEND trial.

What type of cancer is detalimogene targeting?

Detalimogene targets high-risk, BCG-unresponsive non-muscle invasive bladder cancer.

When does enGene plan to submit the BLA?

enGene plans to submit the BLA by the end of this year.

ShareAdd on Google
Tags: ENGN enGene detalimogene BLA submission LEGEND trial BCG-unresponsive NMIBC
Last updated: Nov 11, 2026

Biotech snapshot

Cash runway
$266M liquidity · $6M/mo burn
~40 mo
Low dilution risk
Lead asset
EG-70Phase 2
Superficial Bladder Cancer →

Catalyst track record

+23%
best trade around ENGN's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for ENGN.

See every catalyst's timing & PoA →